BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 34876060)

  • 41. Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE).
    Salama JK; Gu L; Wang X; Pang HH; Bogart JA; Crawford J; Schild SE; Vokes EE; Ready NE
    J Thorac Oncol; 2016 Mar; 11(3):361-9. PubMed ID: 26723241
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
    Igawa S; Shirasawa M; Fukui T; Nishinarita N; Sone H; Ozawa T; Sugita K; Okuma Y; Kurahayashi S; Ono T; Sugimoto A; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Naoki K
    Oncology; 2018; 94(4):207-214. PubMed ID: 29393275
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: systematic review with meta-analysis.
    Lima JP; dos Santos LV; Sasse EC; Lima CS; Sasse AD
    J Thorac Oncol; 2010 Dec; 5(12):1986-93. PubMed ID: 20978445
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic role of pretreatment lung immune prognostic index in extensive-stage small-cell lung cancer treated with platinum plus etoposide chemotherapy.
    Qi W; Zhao S; Chen J
    Cancer Biomark; 2021; 31(2):177-185. PubMed ID: 33896825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).
    Ready NE; Pang HH; Gu L; Otterson GA; Thomas SP; Miller AA; Baggstrom M; Masters GA; Graziano SL; Crawford J; Bogart J; Vokes EE
    J Clin Oncol; 2015 May; 33(15):1660-5. PubMed ID: 25732163
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer.
    Kim DW; Kim HG; Kim JH; Park K; Kim HK; Jang JS; Kim BS; Kang JH; Lee KH; Kim SW; Ryoo HM; Kim JS; Lee KH; Kwon JH; Choi JH; Shin SW; Hahn S; Heo DS
    Cancer Res Treat; 2019 Jan; 51(1):119-127. PubMed ID: 29529858
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Atezolizumab: A Review in Extensive-Stage SCLC.
    Frampton JE
    Drugs; 2020 Oct; 80(15):1587-1594. PubMed ID: 32990939
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study.
    Pujol JL; Daurès JP; Rivière A; Quoix E; Westeel V; Quantin X; Breton JL; Lemarié E; Poudenx M; Milleron B; Moro D; Debieuvre D; Le Chevalier T
    J Natl Cancer Inst; 2001 Feb; 93(4):300-8. PubMed ID: 11181777
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
    Baize N; Monnet I; Greillier L; Geier M; Lena H; Janicot H; Vergnenegre A; Crequit J; Lamy R; Auliac JB; Letreut J; Le Caer H; Gervais R; Dansin E; Madroszyk A; Renault PA; Le Garff G; Falchero L; Berard H; Schott R; Saulnier P; Chouaid C;
    Lancet Oncol; 2020 Sep; 21(9):1224-1233. PubMed ID: 32888454
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage.
    Heigener DF; Manegold C; Jäger E; Saal JG; Zuna I; Gatzemeier U
    Am J Clin Oncol; 2009 Feb; 32(1):61-4. PubMed ID: 19194127
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Correlations between genetic variations of glutathione synthetase gene and the response to platinum-based chemotherapy and prognosis of small cell lung cancer patients].
    Feng T; Li HM; Yuan P; Yu DK; Ma F; Tan WW; Du ZL; Yang J; Huang Y; Lin DX; Xu BH; Tan W
    Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):115-120. PubMed ID: 28219206
    [No Abstract]   [Full Text] [Related]  

  • 53. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.
    Zatloukal P; Cardenal F; Szczesna A; Gorbunova V; Moiseyenko V; Zhang X; Cisar L; Soria JC; Domine M; Thomas M
    Ann Oncol; 2010 Sep; 21(9):1810-1816. PubMed ID: 20231298
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
    Socinski MA; Smit EF; Lorigan P; Konduri K; Reck M; Szczesna A; Blakely J; Serwatowski P; Karaseva NA; Ciuleanu T; Jassem J; Dediu M; Hong S; Visseren-Grul C; Hanauske AR; Obasaju CK; Guba SC; Thatcher N
    J Clin Oncol; 2009 Oct; 27(28):4787-92. PubMed ID: 19720897
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC.
    Arriola E; Wheater M; Galea I; Cross N; Maishman T; Hamid D; Stanton L; Cave J; Geldart T; Mulatero C; Potter V; Danson S; Woll PJ; Griffiths R; Nolan L; Ottensmeier C
    J Thorac Oncol; 2016 Sep; 11(9):1511-21. PubMed ID: 27296105
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR).
    Seckl MJ; Ottensmeier CH; Cullen M; Schmid P; Ngai Y; Muthukumar D; Thompson J; Harden S; Middleton G; Fife KM; Crosse B; Taylor P; Nash S; Hackshaw A
    J Clin Oncol; 2017 May; 35(14):1506-1514. PubMed ID: 28240967
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133).
    Liu SV; Reck M; Mansfield AS; Mok T; Scherpereel A; Reinmuth N; Garassino MC; De Castro Carpeno J; Califano R; Nishio M; Orlandi F; Alatorre-Alexander J; Leal T; Cheng Y; Lee JS; Lam S; McCleland M; Deng Y; Phan S; Horn L
    J Clin Oncol; 2021 Feb; 39(6):619-630. PubMed ID: 33439693
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis.
    Zhou T; Zhang Z; Luo F; Zhao Y; Hou X; Liu T; Wang K; Zhao H; Huang Y; Zhang L
    JAMA Netw Open; 2020 Oct; 3(10):e2015748. PubMed ID: 33074323
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.
    Sanborn RE; Patel JD; Masters GA; Jayaram N; Stephens A; Guarino M; Misleh J; Wu J; Hanna N
    Cancer; 2017 Jan; 123(2):303-311. PubMed ID: 27583688
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
    Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
    Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.